Blocking LPAR5 in thyroid cancer with a selective LPA5 antagonist TCLPA5 attenuated cancer proliferation and migration via PI3K/Akt signaling in vivo and in vitro [76]. Here, LPAR5 is linked to thyroid gland carcinoma.